Boston-based Akili Interactive Labs has partnered with Delivering Scientific Innovation for Autism (DELSIA), a not-for-profit subsidiary of Autism Speaks. DELSIA is funding an efficacy study of Akili’s iOS-based game, called Project: EVO, with children that have high-functioning autism and ADHD.
The trial will be a blind, randomized, placebo-controlled study “that will look to measure cognitive and symptom improvement over one month of device play”, according to Akili. Recruitment will begin toward the end of the year.
Project: EVO is not available in the Apple AppStore — the company aims to get the game FDA-cleared first.
“We are very excited to have the involvement and backing of such an excellent organization that believes in our vision: validated medical products that also have a fun user experience,” Akili COO Eddie Martucci said in a statement. “Our products combine the high engagement and high-resolution data of the tech industry with the strong scientific underpinning of the medical industry. We are excited to advance our products further into the clinic and into the market.”
Project: EVO is designed to assess and treat cognitive issues. To play the game, a user navigates an alien, chosen specifically because it is culture-neutral but also relatable, down a course by tilting a smartphone or tablet back and forth. While navigating the alien, the user must also respond to targets by tapping the screen. Because it is high resolution, the app keeps track of movements every 30 milliseconds and can therefore monitor the user’s behavior and quickly adapt to the player. Keep reading>>